Arrhythmias & electrophysiologyRandomised controlled trial
Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial
- Randomised controlled trial
- multicentre
- double-blind
- superiority
Authors' conclusion
These results show that AI-guided ablation of spatio-temporal dispersion areas in addition to PVI is superior to PVI alone in eliminating AF at 1-year follow-up in patients with persistent and long-standing persistent AF.
Study context
- Population
- Patients with drug-refractory persistent atrial fibrillation (AF)
- Participants
- 187 vs 183
- Comparison
- Artificial intelligence (AI)-guided tailored ablation vs pulmonary vein isolation (PVI) only
- Tailoredn = 187
- Anatomicaln = 183reference
- Primary endpoint
- Freedom from documented AF with or without antiarrhythmic drugs after a single ablation procedure
- Follow-up
- 12 months
Primary result
As reported in the abstract
P < 0.0001
Secondary outcomes
Freedom from any atrial arrhythmia after one ablation
- No significant difference between arms
Safety
Composite safety endpoint (death, cerebrovascular events or treatment-related serious adverse events)
- Did not differ between arms; procedure and ablation times twice as long with tailored ablation
Original publication
Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial. Nat Med. Published 14 February 2025. doi:10.1038/s41591-025-03517-w
Summarised from the published abstract; every number is checked against it